Sera from patients with Crohn's disease break bacterial lipopolysaccharide tolerance of human intestinal epithelial cells via MD-2 activity

Innate Immunity

Volumn 16, Issue 6, 2010, Pages 381-390

  Seksik, Philippe ^a,b   Sokol, Harry ^a,b   Grondin, Virginie ^a   Adrie, Christophe ^c   Duboc, Henri ^a   Pigneur, Benedicte ^a   Thomas, Ginette ^a   Beaugerie, Laurent ^a,b   Trugnan, Germain ^a   Masliah, Joelle ^a   Bachelet, Maria ^a  

^a SORBONNE UNIVERSITÉ   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c Critical Care Department   (France)

Author keywords

inflammatory bowel disease; intestinal epithelial cells; lipopolysaccharide tolerance; MD 2

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; BACTERIUM LIPOPOLYSACCHARIDE; C REACTIVE PROTEIN; DEXAMETHASONE; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; INDOMETACIN; INFLIXIMAB; INTERLEUKIN 1BETA; INTERLEUKIN 8; MYELOID DIFFERENTIATION 2 PROTEIN; NEUTRALIZING ANTIBODY; PROSTAGLANDIN E2; PROTEIN; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD SAMPLING; CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; CULTURE MEDIUM; CYTOKINE RELEASE; DISEASE ACTIVITY; ENTERITIS; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; INFLAMMATION; INTESTINE EPITHELIUM CELL; INTESTINE FLORA; MALE; PROSTAGLANDIN SYNTHESIS; REMISSION; SEPSIS; SERUM; ULCERATIVE COLITIS; WESTERN BLOTTING;

ADULT; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; HT29 CELLS; HUMANS; IMMUNE TOLERANCE; IMMUNITY, MUCOSAL; INTESTINAL MUCOSA; LIPOPOLYSACCHARIDES; LYMPHOCYTE ANTIGEN 96; MALE; MIDDLE AGED;

BACTERIA (MICROORGANISMS);

EID: 78650150386     PISSN: 17534259     EISSN: 17534267     Source Type: Journal    
DOI: 10.1177/1753425909357076     Document Type: Article

References (27)

1. Gioannini TL, Zhang D., Teghanemt A., Weiss JP An essential role for albumin in the interaction of endotoxin with lipopolysaccharide-binding protein and sCD14 and resultant cell activation. J Biol Chem 2002 ; 277: 47818-47825.
2. Gioannini TL, Teghanemt A., Zhang D. et al. Isolation of an endotoxin-MD-2 complex that produces Toll-like receptor 4-dependent cell activation at picomolar concentrations. Proc Natl Acad Sci USA 2004 ; 101: 4186-4191.
3. Visintin A., Latz E., Monks BG, Espevik T., Golenbock DT Lysines 128 and 132 enable lipopolysaccharide binding to MD-2, leading to Toll-like receptor-4 aggregation and signal transduction. J Biol Chem 2003 ; 278: 48313-48320.
4. Kennedy MN, Mullen GED, Leifer CA et al. A complex of soluble MD-2 and lipopolysaccharide serves as an activating ligand for Toll-like receptor 4. J Biol Chem 2004 ; 279: 34698-34704.
5. Shimazu R., Akashi S., Ogata H., Nagai Y., Fukudome K., Miyake K. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med 1999 ; 189: 1777-1782.
6. Viriyakosol S., Mathison JC, Tobias PS, Kirkland TN Structure- function analysis of CD14 as a soluble receptor for lipopolysaccharide. J Biol Chem 2000 ; 275: 3144-3149.
7. Viriyakosol S., Tobias PS, Kitchens RL, Kirkland TN MD-2 binds to bacterial lipopolysaccharide. J Biol Chem 2001 ; 276: 38044-38051.
8. Nagai Y., Akashi S., Nagafuku M. et al. Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat Immunol 2002 ; 3: 667-672.
9. Visintin A., Halmen K., Latz E., Monks BG, Golenbock DT Pharmacological inhibition of endotoxin responses is achieved by targeting the TLR4 coreceptor, MD-2. J Immunol 2005 ; 175: 6465-6472.
10. Schromm AB, Lien E., Henneke P. et al. Molecular genetic analysis of an endotoxin nonresponder mutant cell line: a point mutation in a conserved region of MD-2 abolishes endotoxin-induced signaling. J Exp Med 2001 ; 194: 79-88.
11. Visintin A., Mazzoni A., Spitzer JA, Segal DM Secreted MD-2 is a large polymeric protein that efficiently confers lipopolysaccharide sensitivity to Toll-like receptor 4. Proc Natl Acad Sci USA 2001 ; 98: 12156-12161.
12. Lenoir C., Sapin C., Broquet AH et al. MD-2 controls bacterial lipopolysaccharide hyporesponsiveness in human intestinal epithelial cells. Life Sci 2008 ; 82: 519-528.
13. Pugin J., Stern-Voeffray S., Daubeuf B., Matthay MA, Elson G., Dunn-Siegrist I. Soluble MD-2 activity in plasma from patients with severe sepsis and septic shock. Blood 2004 ; 104: 4071-4079.
14. Cario E., Golenbock DT, Visintin A., Runzi M., Gerken G., Podolski DK Trypsin-sensitive modulation of intestinal epithelial MD-2 as mechanism of lipopolysaccharide tolerance. J Immunol 2006 ; 176: 4258-4266.
15. Rembacken BJ, Snelling M., Hawkey PM, Chalmers DM, Axon AT Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis. Lancet 1999 ; 354: 635-639.
16. Schultz M., Sartor RB Probiotics in inflammatory bowel disease. Gastroenterology 2000 ; 95: S19 - S21.
17. Teghanemt A., Widstrom RL, Gioaninni TL, Weiss JP Isolation of monomeric and dimeric secreted (s) MD-2: endotoxin sCD14 and Toll-like receptor 4 ectodomain selectively react with the monomeric from of sMD-2. J Biol Chem 2008 ; 283: 21881-21889.
18. Lennard-Jones JE Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989 ; 170: 2-6.
19. Cario E., Podolsky DK Differential alteration in intestinal epithelial cell expression of Toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun 2000 ; 68: 7010-7017.
20. Bantel H., Schmitz LM, Raible A., Gregor M., Schulze-Osthoff K. Critical role of nuclear factor-kB and stress-activated protein kinases in steroid unresponsiveness. FASEB J 2002 ; 16: 1832-1850.
21. Komatsu M., Kobayashi D., Saito K. et al. Tumor necrosis factor-alpha in serum from patients with inflammatory bowel disease as measured by a highly sensitive immuno-PCR. Clin Chem 2001 ; 47: 1297-1301.
22. Jia HP, Kline JN, Penisten A. et al. Endotoxin responsiveness of human airway epithelia is limited by low expression of MD-2. Am J Physiol 2004 ; 287: L428 - L437.
23. Taireja J., Dileepan K., Puri S. et al. Human conjunctival epithelial cells lack lipopolysaccharide responsiveness due to deficient expression of MD-2 but respond after interferon-gamma priming or soluble MD-2 supplementation. Inflammation 2005 ; 29: 170-181.
24. Tissieres P., Dunn-Siegrist I., Schappi M. et al. Soluble MD-2 is an acute phase protein and an opsonin for Gram-negative bacteria. Blood 2008 ; 111: 2122-2131.
25. Sonnenberg A. Seasonal variation of enteric infections and inflammatory bowel disease. Inflamm Bowel Dis 2008 ; 14: 955-959.
26. Riley SA, Mani V., Goodman MJ, Lucas S. Why do patients with ulcerative colitis relapse? Gut 1990 ; 31: 179-183. (Pubitemid 20092152)
27. Gupta RB, Harpaz N., Itzkowitz S. et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 2007 ; 133: 1340-1341.